Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. - Wikidata - wikimedia - TriplyDB

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.

http://www.wikidata.org/entity/Q30275254

about

Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses.The role of tumor microenvironment in resistance to anti-angiogenic therapy.

P2860

Q50055506-3A5B1E99-EE58-437B-B6E9-401086F63203 Q52645823-5289271B-6917-46F8-8A65-35F46EC3FC84

P2860

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.

http://www.wikidata.org/entity/Q30275254

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Immune modulation associated w ...... in patients with glioblastoma.

@ast

Immune modulation associated w ...... in patients with glioblastoma.

@en

type

label

Immune modulation associated w ...... in patients with glioblastoma.

@ast

Immune modulation associated w ...... in patients with glioblastoma.

@en

prefLabel

Immune modulation associated w ...... in patients with glioblastoma.

@ast

Immune modulation associated w ...... in patients with glioblastoma.

@en

P1433

Q30275254-E6A03A24-9F29-4B16-901E-1D14C06D1B97

P1476

Q30275254-472A9039-AF47-4A54-9CD8-F6F04EC07D0E

P2093

Q30275254-236CC36B-69EA-4E78-98DA-175AE38D4868

Q30275254-2820BFB5-FC33-4A27-AF60-3234B00ABEA3

Q30275254-2DBCCEF9-5F79-42D2-BE16-4D7A4758AC2A

Q30275254-3DE76866-1069-4EC2-81A6-1E5859632ED4

Q30275254-450F55E5-C637-48FF-B643-E87CBECD2FB2

Q30275254-61EABA9F-98FD-404D-AECF-10270E2FA6AE

Q30275254-638E0BF8-F7AB-45D9-8A8D-1B3F7BDFE8F4

Q30275254-B0187B53-EC57-4E8A-B8F3-C2C47A9FA1E3

Q30275254-C31CAA4B-503F-4C75-928C-AB368135AFAE

Q30275254-C38175A2-80BB-48AE-BC32-BF4E602BAC37

P2860

Q30275254-038E8E85-009D-4728-8F39-235BAAE3FE82

Q30275254-143298A4-3556-412C-BBEA-0613E8DC7893

Q30275254-18847DAE-B0E4-48E2-9640-EAC831F3758F

Q30275254-19ABBCD5-2AC4-4DDE-B1E9-29EC2BC2B7C1

Q30275254-1BFC6D1E-5183-4490-A283-00CD7B457709

Q30275254-31EA7257-C632-48AA-9129-4F9DEFFA05FA

Q30275254-34D1A8E4-383A-43A4-BCF5-9EBE35BF186E

Q30275254-3C63EE1B-C298-4AE2-B585-0FC185EEEA69

Q30275254-4111EA47-B422-4394-90C0-9A530EC0C3C9

Q30275254-45377048-5458-481E-882C-6221255C47E9

P2888

Q30275254-58999014-72BD-4427-BB66-083946BB684D

P304

Q30275254-3A9B1D99-A738-4254-8784-24A576ADEFF5

P31

Q30275254-6D0710AD-7274-4768-A419-3199C023C4AE

P356

Q30275254-82ECBAD2-A9D3-44D8-9A57-4FBF5AEA0959

P433

Q30275254-B7D7B087-A5CF-47E7-994D-A7BD83B98270

P478

Q30275254-74633FAD-7AEC-4C7A-B44D-7576B7BB79AE

P50

Q30275254-20EE3270-32D3-46AC-B307-AB50BB5DE73A

P577

Q30275254-0843E4D8-378B-471A-9F28-0B51F20C57CE

P6179

Q30275254-07FA21B6-0E16-4841-9C33-B74E125FDF7D

P698

Q30275254-370909D9-F966-4C51-AE75-D6B3E49869A9

P921

Q30275254-8C2407F5-AA95-4CDD-A1F4-C4F8048AD023

P356

S00262-016-1941-3

P1433

Cancer Immunology, Immunotherapy

P1476

Immune modulation associated w ...... in patients with glioblastoma.

@en

P2093

Alissa A Thomas

http://www.w3.org/2001/XMLSchema#string

Arti B Gaur

http://www.w3.org/2001/XMLSchema#string

Brock C Christensen

http://www.w3.org/2001/XMLSchema#string

Camilo E Fadul

http://www.w3.org/2001/XMLSchema#string

Chery A Whipple

http://www.w3.org/2001/XMLSchema#string

Gregory J Tsongalis

http://www.w3.org/2001/XMLSchema#string

Jan L Fisher

http://www.w3.org/2001/XMLSchema#string

Lionel D Lewis

http://www.w3.org/2001/XMLSchema#string

Marc S Ernstoff

http://www.w3.org/2001/XMLSchema#string

Melissa C Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Control of the immune response by pro-angiogenic factors

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Platelets actively sequester angiogenesis regulators.

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

Biomarkers of response and resistance to antiangiogenic therapy.

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.

Immature myeloid cells and cancer-associated immune suppression.

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

P2888

s00262-016-1941-3

P304

379-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-016-1941-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032166798

http://www.w3.org/2001/XMLSchema#string

P698

27942839

http://www.w3.org/2001/XMLSchema#string

P921